European Archives - European Medical Journal

Trial Demonstrates Talazoparib Extends Prostate Cancer Survival

The TALAPRO-2 study enrolled 805 patients from 200 centres across 26 countries, including North America, Europe, Israel, South America, South Africa, and the Asia–Pacific region.

Obesity Limits Full Benefit of Asthma Biologics

A UK registry study shows asthma biologics improve outcomes across BMI groups, but obese patients remain more likely to have uncontrolled disease.

New Blood Test Shows High Accuracy for Early Lung Cancer Detection

A promising new study has identified a highly accurate, non-invasive method to diagnose non-small cell lung cancer (NSCLC) using a blood test based on tRNA signatures.

Digital Nursing Care Reduces Itching and Improves Sleep in AD

This study evaluated a clustered nursing care model, delivered via an online platform, for adults with atopic dermatitis.

The Benefits of Biosimilars in Clinical Practice

Join moderator Sue Saville with experts Gerd Burmester and Dr. Luke Nicholson as they explore the impact of biosimilars in healthcare…

Pain Blocking May Not Reduce Inflammation After Liver Surgery

In this randomised prospective study, 72 living liver donors scheduled for right hepatectomy were enrolled and divided into two groups.

Vitamin D Supplementation Reduces Pain and Disease Activity in Rheumatoid Arthritis

A randomised double-blind trial in Kosovo found that 4,000 IU of vitamin D daily significantly reduced pain and disease activity in rheumatoid arthritis patients after six months of treatment.

Aspirin Not Recommended for Primary Prevention in Older Adults

Study finds no long-term cardiovascular benefit from aspirin in healthy older people, but highlights increased bleeding risk.

Higher Cancer Risk with JAK Inhibitors in Rheumatoid Arthritis Treatment

Researchers analyzed over 6,500 treatment episodes between January 2017 and December 2020, with follow-up through June 2024

Novel Oral Polio Vaccines Show Strong Safety and Immune Response

A Phase 1 USA trial finds novel oral polio vaccines nOPV1 and nOPV3 to be safe, highly immunogenic, and comparable to Sabin-strain vaccines, paving the way for Phase 2 studies.